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Despite intense interest in designing positive allosteric modulators (PAMs) as selective drugs of the 
adenosine A1 receptor (A1AR), structural binding modes of the receptor PAMs remain unknown. Using 
the first X-ray structure of the A1AR, we have performed all-atom simulations using a robust Gaussian 
accelerated molecular dynamics (GaMD) technique to determine binding modes of the A1AR allosteric 
drug leads. Two prototypical PAMs, PD81723 and VCP171, were selected. Each PAM was initially 
placed at least 20 Å away from the receptor. Extensive GaMD simulations using the AMBER and NAMD 
simulation packages at different acceleration levels captured spontaneous binding of PAMs to the 
A1AR. The simulations allowed us to identify low-energy binding modes of the PAMs at an allosteric 
site formed by the receptor extracellular loop 2 (ECL2), which are highly consistent with mutagenesis 
experimental data. Furthermore, the PAMs stabilized agonist binding in the receptor. In the absence of 
PAMs at the ECL2 allosteric site, the agonist sampled a significantly larger conformational space and 
even dissociated from the A1AR alone. In summary, the GaMD simulations elucidated structural binding 
modes of the PAMs and provided important insights into allostery in the A1AR, which will greatly 
facilitate the receptor structure-based drug design.
G-protein-coupled receptors (GPCRs) are key cellular signaling proteins and represent primary targets of ~1/3 
of currently marketed drugs1. Four GPCR subtypes, the A1, A2A, A2B and A3 receptors, mediate the effects of 
adenosine, an endogenous nucleoside modulator that plays a critical role in cytoprotective function2. In particu-
lar, preclinical studies suggest the adenosine A1 receptor (A1AR) is an important novel drug target for treating 
human diseases such as ischemia-reperfusion injury and neuropathic pain3. However, the high conservation of 
the endogenous agonist binding (“orthosteric”) site across the different adenosine receptor subtypes, has hindered 
the therapeutic development of A1AR agonists due to off-target side effects4. Furthermore, since the A1AR is 
expressed in different human tissues, including the heart and brain, traditional agonists can also cause on-target 
side effects. An alternative strategy involves the development of positive allosteric modulators (PAMs), which 
through binding to a topographically distinct (“allosteric”) site on the receptor, can increase the responsiveness 
of A1AR to endogenous adenosine within the local regions of its elevated production. PAMs have the potential to 
overcome the current limitations associated with orthosteric agonists and thus are a promising approach for the 
development of subtype selective A1AR therapeutics that are not associated with unwanted effects5–10.
The first A1AR PAM, PD81723, was identified by Bruns and coworkers in 199011,12. Since then, a number of 
research groups have performed extensive structure-activity relationship (SAR) studies with the aim to improve 
the compound pharmacology and chemical properties11,13–21. Generally, the success of SAR studies has been 
limited due to a lack of structural basis for chemical modifications of the reference compound PD81723. For 
instance, heterocycles were designed to replace the phenyl group at the 3-position of the thiophene ring in 
PD81723 to increase solubility and improve binding affinity through a predicted hydrogen bond with the A1AR 
allosteric site, unfortunately the synthesized derivatives were found to be less potent than PD8172322. However, 
despite the limitations, SAR programs have yielded PD81723 derivatives with improved pharmacology including 
the T6223,24 and VCP17125. Notably, T62, evaluated by King Pharmaceuticals progressed to Phase IIB clinical trial 
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(for neuropathic pain), but failed due to lack of efficacy23,24. Overall, these compounds still suffer from major 
limitations for pharmaceutical use, such as low solubility, affinity and cooperativity.
To date, structural information regarding PAM interactions with the A1AR has been largely unavailable to 
guide previous drug design efforts aimed towards the development of therapeutically effective A1AR PAMs5. 
Mutagenesis and molecular modeling studies have suggested that the A1AR allosteric site may reside within 
the second extracellular loop (ECL2)26,27, however the precise location of the allosteric site and the molecular 
mechanisms underlying the allosteric modulation of PD81723 and other PAMs remain unclear. Recently, the 
first X-ray crystal structure of the A1AR (PDB: 5UEN) was determined by Christopoulos and coworkers28. In the 
structure, the A1AR was bound to an irreversible antagonist DU172, which forms a covalent bond with Tyr2717.36 
in the transmembrane (TM) helix 7; superscript denoting Ballesteros-Weinstein residue numbering29. Compared 
with previous X-ray structures of the A2AAR30,31, the A1AR exhibits a significantly wider extracellular cavity with 
a distinct conformation of the ECL2. Another similar X-ray structure was determined for the A1AR bound by 
the antagonist in the inactive state32. The X-ray structures serve as an excellent starting point for computational 
modeling and structure-based drug discovery of the A1AR.
Molecular dynamics (MD) is a powerful computational technique for simulating biomolecular dynamics on 
an atomistic level33. For GPCRs, MD has been applied to simulate binding of both orthosteric and allosteric 
ligands28,34,35. Using the specialized supercomputer Anton, Dror et al. performed microsecond-timescale MD 
simulations on the β1 and β2 adrenergic receptors (β1AR and β2AR)34. These simulations showed that antago-
nist and agonist ligands entered the receptor orthosteric site through an opening between ECL2-ECL3, which 
was suggested to be a dominant binding pathway of GPCR drugs. Subsequent Anton MD simulations captured 
the same orthosteric ligand binding pathway for the M2 and M3 muscarinic acetylcholine GPCRs (mAChRs)28. 
Binding of several known negative allosteric modulators (NAMs) to the extracellular vestibule of the M2 receptor 
was observed in further Anton MD simulations35. The modulators formed cation-π interactions with aromatic 
residues in the receptor extracellular vestibule. The extracellular allosteric binding mode was confirmed by muta-
tion experiments and later by the X-ray structure of the active M2 receptor that is recognized by a PAM36. Despite 
these successes, direct MD simulations are computationally expensive for studying protein-ligand binding. They 
often suffer from insufficient sampling of slow ligand binders28 and cannot capture ligand dissociation due to 
limited simulation timescales.
During the last several decades, many enhanced sampling methods have been developed to improve MD sim-
ulations37–43. Among these methods, metadynamics44,45, random acceleration MD46,47, steered MD48, temperature 
accelerated MD (TAMD)28,49, accelerated MD (aMD)50,51 and Gaussian aMD (GaMD)52–54 have been applied to 
simulate ligand binding to GPCRs55. Metadynamics was applied to simulate binding of a PAM to the δ-opioid 
receptor in the presence of an agonist56 and calculate ligand binding free energies in the β2AR57. We performed 
aMD simulations on binding of the tiotropium antagonist, acetylcholine agonist and arecoline partial agonist 
to the M3 muscarinic receptor58. In comparison with the previous Anton MD simulations28, aMD captured a 
similar ligand binding pathway, but with significant speedup (~80 times faster for agonist binding to the receptor 
orthosteric ligand-binding site). Using GaMD that provides unconstrained enhanced sampling and improved 
free energy calculations52–54, we also captured spontaneous binding of the agonist acetylcholine and identified its 
low-energy binding sites in the M3 receptor53. The energetically preferred pathway of agonist binding identified 
from the GaMD simulation was similar to that found in previous long-timescale cMD34 and aMD58 simulations. 
Furthermore, we successfully applied GaMD to capture both dissociation and binding of the arecoline partial 
agonist in the M2 receptor59. Therefore, GaMD is well suited for investigating ligand binding of large biomolecules 
such as GPCRs.
In this study, we have applied GaMD to simulate binding of allosteric drug leads to the A1AR. Extensive 
GaMD simulations using the AMBER and NAMD simulation packages at different acceleration levels captured 
spontaneous binding of two prototypical PAMs to the A1AR. The GaMD simulations also allowed free energy cal-
culations to identify low-energy binding modes of the PAMs at the putative allosteric site formed by ECL2 of the 
receptor, which is highly consistent with the mutation experimental data. Furthermore, PAM binding was found 
to stabilize agonist binding at the receptor orthosteric site. Therefore, GaMD simulations have provided a greater 
understanding of the structural binding modes and allosteric effects of PAMs at the A1AR.
Results
GaMD simulations captured spontaneous binding of PAMs. Using the first X-ray crystal structure 
of the A1AR (PDB: 5UEN, Fig. 1A)60, we have performed all-atom GaMD simulations to investigate binding 
of two prototypical PAMs, PD8172311,12 and VCP17125 (Fig. 1B). The antagonist was removed from the X-ray 
structure and the agonist 5′-N-ethylcarboxamidoadenosine (NECA) placed in the receptor with atomic coordi-
nates extracted from the A2AAR X-ray structure (PDB: 2YDV), after aligning the two receptor transmembrane 
domains. GaMD simulations of the NECA-bound A1AR were performed in the absence and presence of two 
PAMs, PD81723 and VCP171. Each PAM was initially placed at least 20 Å away from the receptor (Fig. 1C). 
Multiple independent GaMD simulations were performed using AMBER and NAMD at different acceleration 
levels to investigate the PAM binding processes (Table 1).
With AMBER, GaMD simulations boosted both the total and dihedral energetic terms (“dual-boost 
GaMD”)52 on the NECA-bound A1AR, NECA-bound A1AR in the presence of PD81723 and NECA-bound 
A1AR in the presence of VCP171 provided boost potentials of 17.89 ± 5.23 kcal/mol, 18.36 ± 5.29 kcal/mol and 
17.66 ± 5.23 kcal/mol, respectively. In comparison, dual-boost GaMD simulations using NAMD showed boost 
potentials of 11.77 ± 3.07 kcal/mol and 11.14 ± 3.07 kcal/mol for the NECA-bound A1AR in the absence and 
presence of PD81723, respectively. Further GaMD simulations were performed by boosting the dihedrals only 
(“dihedral GaMD”)53 using NAMD. The boost potentials were 6.04 ± 2.23 kcal/mol and 5.65 ± 2.14 kcal/mol for 
the NECA-bound A1AR in the absence and presence of the PD81723, respectively (Table 1). In principle, greater 
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average and standard deviation of the boost potential (∆Vavg and σ∆V) lead to higher acceleration in the biomo-
lecular structural fluctuations. Therefore, the AMBER version of GaMD appeared to provide higher acceleration 
than the NAMD version, due to slightly different algorithms implemented for computing the potential statistics 
in the two packages (SI Method).
Despite the different acceleration levels, all the GaMD simulations successfully captured spontaneous bind-
ing of PD81723 and VCP171 to the A1AR. Traces of the diffusing PAMs obtained in GaMD simulations with 
PD81723 and VCP171 are shown in Figs S1 and S2, respectively. Overall, PD81723 and VCP171 bound to a 
pocket formed by the ECL2 with the highest probability, although the PAMs could also transiently visit other 
regions of the A1AR. This agrees with previous mutagenesis experiments that alanine substitutions of residues in 
the ECL2 affected binding of the PAMs26,27. Therefore, the GaMD simulations successfully captured spontaneous 
binding of the A1AR PAMs PD81723 and VCP171.
GaMD predicted binding poses of PD81723 were consistent with structure-function 
data. Structural clustering of the PAMs and calculated free energies of the resulting structural clusters were 
performed on the GaMD simulation trajectories (see details in Methods). The lowest-energy binding poses of 
PD81723 at the ECL2 allosteric site obtained from dual-boost GaMD simulations using AMBER, dual-boost 
GaMD simulations using NAMD and dihedral GaMD simulations using NAMD are shown in Fig. 2A–C, respec-
tively. Overall, PD81723 exhibited similar binding poses at the ECL2 allosteric site in the GaMD simulations 
at different acceleration levels. The trifluoro-phenyl group all pointed in the same direction towards Trp156, 
although the 2-amino-thiophene group was able to rotate slightly in the bottom part of the ECL2 pocket. The 
carbonyl oxygen always pointed towards the solvent, favoring hydrophilic interactions. The phenyl ring aligned 
in parallel with the short helix of ECL2, forming favorable hydrophobic interactions with protein residues Phe77, 
Val152, Ala155, Pro165 and Ile167. Common residues that were identified within 5 Å of the bound PD81723 in 
Figure 1. (A) X-ray structure of the DU172 antagonist-bound adenosine A1 receptor (A1AR) (PDB: 5UEN), 
(B) the structure of the two prototypical A1AR positive allosteric modulators (PAMs), PD81723 and VCP171, 
used in this study and (C) computational model used for the simulations. The receptor was inserted into a 
POPC lipid bilayer and solvated in an aqueous medium of 0.15 M NaCl. After removal of antagonist from the 
A1AR X-ray structure, NECA was placed in the orthosteric pocket with atomic coordinates copied from the 
A2AAR X-ray structure (PDB: 2YDV) after aligning the two receptor transmembrane domains. Four molecules 










GaMD_Dual (AMBER) 500 ns × 5 17.89 5.23 51 —
GaMD_Dual (NAMD) 300 ns × 5 11.77 3.07 4 —
GaMD_Dih (NAMD) 200 ns × 5 6.04 2.23 6 —
A1AR + NECA + PD81723
GaMD_Dual (AMBER) 500 ns × 5 18.36 5.29 2 2
GaMD_Dual (NAMD) 300 ns × 5 11.14 3.07 12 9
GaMD_Dih (NAMD) 200 ns × 5 5.65 2.14 1 1
A1AR + NECA + VCP171 GaMD_Dual (AMBER) 500 ns × 5 17.66 5.23 73 4
Table 1. Summary of GaMD simulations performed on the adenosine A1 receptor (A1AR). ∆Vavg and σ∆V 
are the average and standard deviation of the GaMD boost potential. The number of structural clusters of 
the orthosteric agonist NECA are calculated from the GaMD simulations in the absence or presence of PAM 
binding, PD81723 or VCP171, to the ECL2 allosteric site.
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the lowest-energy poses from the GaMD simulations included Ala155, Ala159, Trp156, Pro165, Ile167, Phe77 
and Lys173. Moreover, residues Asn148, Ala151, Val152, Glu153, Ser161, Val166, Lys168, Glu172 and Val174 
appeared within 5 Å of PD81723 in one or two of the binding poses (Fig. 2A–C).
The lowest-energy binding poses of PD81723 obtained from the GaMD simulations were highly consistent 
with site-directed mutagenesis experiments26,27. Particularly, alanine substitution of Asn147, Asn148, Ser161, 
Pro165, Val166, Ile167, Glu170, Lys173 or Ile175 significantly enhanced the binding affinity (pKB) of PD81723, 
while mutation of Glu172 to alanine had the opposite effect (Fig. 2D). Alanine substitutions of residues Asn147, 
Asn148, Gly160, Ser161, Lys173 and Glu170 decreased the binding cooperativity (logαI) between PD81723 and 
NECA at the A1AR (Fig. 2E). Alanine substitutions of Asn148, Glu153, Ser161 and Ile167 decreased PAM efficacy 
logτB(C) (Fig. 2F). Finally, mutation of Glu172 to alanine increased the functional cooperativity (logαβ) between 
PD81723 and NECA for A1AR-mediated inhibition of cAMP accumulation (Fig. 2G).
GaMD predicted binding mode of VCP171 was consistent with structure-function data. The 
lowest-energy binding mode of VCP171 identified from dual-boost GaMD simulations using AMBER is shown 
in Fig. 3A. VCP171 also recognized the putative allosteric site formed by the ECL2 and adopted a similar orien-
tation to PD81723. The trifluoro-phenyl group was parallel to the short helix in ECL2. The thiol group pointed 
towards Asn148 and the additional phenyl group formed hydrophobic interactions with the Phe77 and Ile167 
side chains (Fig. 3A). Residues found within 5 Å of the bound VCP171 included Phe77, Asn148, Ala151, Val152, 
Ala155, Ile167, Lys168, Glu172 and Lys173 (Fig. 3A). The majority of interacting residues were shared between 
the PAMs PD81723 and VCP171 (Fig. 2).
Residues found within 5 Å of the bound VCP171 were highly consistent with site-directed mutagenesis exper-
iments26,27. Notably, mutation of Glu172 to alanine significantly decreased binding affinity of VCP171 (Fig. 3B). 
Alanine substitution of Trp146 and Trp156 decreased binding cooperativity between VCP171 and NECA at the 
A1AR (Fig. 3C). Alanine substitution of Asn148, Glu153, Arg154, Ser161, Ile167 and Ile175 decreased the recep-
tor efficacy (Fig. 3D). Finally, alanine substitution of Arg154, Ser161, Trp156, Val174 and Ile175 decreased the 
functional cooperativity between VCP171 and NECA for A1AR-mediated inhibition of cAMP accumulation 
(Fig. 3E). Therefore, the binding mode of VCP171 obtained from the GaMD simulations was supported by exper-
imental structure-function analysis26,27.
Figure 2. GaMD simulations predicted the A1AR PAM PD81723 recognized an allosteric site defined by 
extracellular loop 2 (ECL2): (A–C) Low-energy binding modes of PD81723 identified from (A) dual-boost 
GaMD simulations using AMBER, (B) dual-boost GaMD simulations using NAMD and (C) dihedral-boost 
GaMD simulations using NAMD. The receptor, orthosteric agonist NECA and PAM PD81723 are shown in 
ribbons, spheres and sticks, respectively. Residues found within 5 Å of the bound PD81723 are highlighted 
in balls-and-sticks. (D–G) A1AR residues for which alanine substitution were shown in a previous structure-
function study27 to significantly decrease (orange) or enhance (red) PD81723 affinity (D), binding cooperativity 
(E), efficacy (F) or functional cooperativity (G).
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PAM binding stabilized agonist binding within the A1AR orthosteric site. Subsequent analysis 
assessed the influence of PAMs on NECA binding within the A1AR orthosteric site. Structural clusters of the 
agonist NECA were obtained in the absence and presence of PAM binding (Fig. 4). In the NECA-bound A1AR 
simulation system in the absence of an allosteric ligand, NECA sampled a large conformational space in the 
orthosteric pocket. Numerous structural clusters of NECA were identified from simulations of the NECA-bound 
A1AR system using dual-boost GaMD with AMBER (51 clusters, Fig. 4A), dual-boost GaMD with NAMD (4 
clusters, Fig. 4B) and dihedral-boost GaMD with NAMD (6 clusters, Fig. 4C). In dual-boost GaMD simulations 
with AMBER, which provided the highest acceleration (Table 1), the NECA agonist was able to explore the entire 
orthosteric pocket (Fig. 4A). Whereas in the dual-boost and dihedral GaMD simulations using NAMD with 
lower acceleration levels, NECA sampled a smaller conformational space (Fig. 4B,C). Accordingly, the RMSD 
of NECA relative to the crystal conformation obtained from the 2YDO X-ray structure of the A2AAR with two 
receptor TM domains aligned exhibited large variations during the AMBER dual-boost GaMD simulations 
(Fig. S3A), while the NAMD dual-boost and dihedral GaMD simulations showed smaller variations in the ago-
nist RMSDs (Fig. S3B and S3C).
During GaMD simulations of the NECA-bound A1AR in the presence of PD81723, RMSD of NECA typically 
remained <5 Å with small variations (Fig. S4), except that it reached ~9 Å in one of the five dual-boost GaMD 
simulations using NAMD (“Sim5” in Fig. S4B). This suggested that PD81723 was able to stabilize NECA bind-
ing in the orthosteric site. We tracked PD81723 diffusion and identified structural clusters of NECA without 
and with PD81723 bound at the ECL2 allosteric site. Different numbers of structural clusters for the orthosteric 
agonist NECA with no PD81723 bound at the ECL2 allosteric site were obtained during the dual-boost GaMD 
simulations with AMBER (2 clusters), dual-boost GaMD simulations with NAMD (12 clusters) and dihedral 
Figure 3. GaMD simulations predicted the A1AR PAM VCP171 recognized an allosteric site defined by 
extracellular loop 2 (ECL2): (A) Low-energy binding mode of VCP171 identified from dual-boost GaMD 
simulations using AMBER. The receptor, orthosteric agonist NECA and PAM VCP171 are shown in ribbons, 
spheres and sticks, respectively. Residues found within 5 Å of the bound VCP171 are highlighted in balls-and-
sticks. (B–E) A1AR residues for which alanine substitution were shown in a previous structure-function study27 
to significantly decrease (orange) or enhance (red) VCP171 affinity (B), binding cooperativity (C), efficacy (D) 
or functional cooperativity (E).
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GaMD simulations with NAMD (1 cluster) (Fig. 4D–F, Table 1). In comparison, PD81723 binding to the ECL2 
allosteric site led to fewer structural clusters and smaller conformational space of NECA in the orthosteric pocket 
(Fig. 4 and Table 1). During the AMBER dual-boost GaMD, NAMD dual-boost GaMD and NAMD dihedral 
GaMD simulations, the number of structural clusters identified for NECA was 2, 9 and 1, respectively (Table 1). 
Figure 4. PD81723 stabilized NECA binding within the A1AR orthosteric site: (A–C) structural clusters of 
NECA identified in simulations of the “A1AR + NECA” system using (A) dual-boost GaMD with AMBER, 
(B) dual-boost GaMD with NAMD and (C) dihedral-boost GaMD with NAMD. (D–F) structural clusters 
of NECA identified in simulations of the “A1AR + NECA + PD81723” system with no PD81723 bound at 
the ECL2 allosteric site using (D) dual-boost GaMD with AMBER, (E) dual-boost GaMD with NAMD and 
(F) dihedral-boost GaMD with NAMD. (G–I) structural clusters of NECA identified in simulations of the 
“A1AR + NECA + PD81723” system with PD81723 bound at the ECL2 allosteric site using (G) dual-boost 
GaMD with AMBER, (H) dual-boost GaMD with NAMD and (I) dihedral-boost GaMD with NAMD. 
The receptor, orthosteric agonist (NECA) and PAM (PD81723) are shown in ribbons, sticks and spheres, 
respectively. NECA clusters are colored by the potential of mean force (PMF) in a green(0 kcal/mol)-white-
red(8 kcal/mol) scale and the NECA conformation extracted from the 2YDV X-ray structure of the A2AAR with 
two receptor transmembrane domains aligned is shown in orange for reference.
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Upon binding of PD81723 at the ECL2 allosteric site, NECA sampled a smaller conformational space. Structural 
clusters of NECA identified in simulations of the “A1AR + NECA + PD81723” system with PD81723 bound at the 
ECL2 allosteric site using dual-boost GaMD with AMBER, dual-boost GaMD with NAMD and dihedral-boost 
GaMD with NAMD are shown in Fig. 4G–I. Movement of the NECA agonist was greatly reduced in the presence 
of PD81723. Therefore, the PD81723 PAM stabilized agonist binding at the orthosteric site of the A1AR.
Agonist dissociation was observed in the absence of PAM binding. Dual-boost GaMD simulations 
using AMBER were also performed on the system of NECA-bound A1AR in the presence of the VCP171 PAM. 
While NECA showed small movements with mostly <10 Å RMSD relative to the 2YDV crystal conformation 
(Fig. S5), it escaped out of the receptor with >20 Å RMSD in one of the five GaMD simulations (“Sim3”). The 
structural clusters of NECA were identified from the GaMD simulations with and without VCP171 bound at the 
ECL2 allosteric site (Fig. 5). VCP171 binding to ECL2 greatly limited the conformational space of NECA agonist 
with only four structural clusters identified in the receptor orthosteric pocket (Fig. 5A and Table 1).
In the absence of VCP171 binding to the ECL2 allosteric site, NECA sampled a significantly larger conforma-
tional space and even dissociated from the A1AR (Fig. 5B). A large number of structural clusters (73 clusters) were 
identified for the diffusing NECA (Table 1). The lowest energy clusters depict an agonist dissociation pathway, 
which connect the receptor orthosteric site, extracellular opening between the ECL2/ECL3, the allosteric site 
formed by the ECL2 and finally the solvent (Fig. 5B). This is consistent with previous simulation findings that 
ligand binding through the ECL2/ECL3 opening is an energetically preferred pathway of class A GPCRs34,49,58,59. 
Furthermore, the open pocket formed by only the ECL2 serves as an additional metastable binding site of the 
agonist, as well as the target site of PAMs in the A1AR.
PAM binding promotes the formation of a salt bridge E172ECL2-K265ECL3 in the A1AR extra-
cellular vestibule. We have examined protein residue interactions in the A1AR extracellular domains to 
understand the allosteric mechanism of stabilized agonist interactions within the orthosteric site in the pres-
ence of PAM binding to ECL2. Simulation analysis revealed a salt bridge between Glu172ECL2-Lys265ECL3 in the 
extracellular mouth of the A1AR. In particular, the favorable hydrophobic interactions between the PAM and 
ECL2 within the allosteric pocket positioned Glu172ECL2 to extend its side chain towards residue Lys265ECL3. 
The Glu172ECL2-Lys265ECL3 salt bridge in the A1AR extracellular mouth was then closed upon PAM binding to 
the ECL2 allosteric site (Fig. 6). This predicted interaction is consistent with mutation experimental data that 
substitution of Glu172 to alanine significantly affected binding affinity of PD81723 and functional cooperativity 
between the PAM and agonist26,27 (Fig. 2).
A 2D PMF profile of the Glu172ECL2-Lys265ECL3 distance and RMSD of the NECA agonist relative to the 
starting bound conformation was calculated from AMBER dual-boost GaMD simulations of the NECA-bound 
A1AR system (Fig. 6A). Three low-energy conformational states, “open”, “intermediate” and “closed”, were iden-
tified from the free energy profile. Notably, this salt bridge adopted the open conformation in the X-ray structure 
of antagonist DU172-bound A1AR (PDB: 5UEN)61 and intermediate conformation in the cryo-EM structure 
of adenosine-Gi-bound A1AR (PDB: 6D9H)62, for which the Glu172ECL2-Lys265ECL3 distance is 14.82 Å/15.14 Å 
Figure 5. Structural clusters of NECA identified in dual-boost GaMD simulations using AMBER of the 
“A1AR + NECA + VCP171” system: (A) binding of NECA in the A1AR orthosteric site was stabilized upon 
VCP171 binding to the ECL2 allosteric site. (B) Dissociation of NECA was observed in the absence of VCP171 
binding to the ECL2 allosteric site. The receptor, orthosteric agonist (NECA) and PAM (VCP171) are shown in 
ribbons, sticks and spheres, respectively. NECA clusters are colored by free energy in a green(0 kcal/mol)-white-
red(8 kcal/mol) scale and the NECA conformation extracted from the 2YDV X-ray structure of the A2AAR with 
two receptor transmembrane domains aligned is shown in orange for reference.
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(dimer in the 5UEN structure) and 7.12 Å, respectively. Upon PAM binding to the A1AR, the salt bridge changed 
to the closed conformation with 3.0 Å distance between the Glu172ECL2 and Lys265ECL3 (Fig. 6B). In addition, 
2D PMF profiles of the Glu172ECL2-Lys265ECL3 distance and the occupancy of PAMs at the ECL2 allosteric 
site were calculated from AMBER dual-boost GaMD simulations of the “A1AR + NECA + PD81723” and 
“A1AR + NECA + VCP171” systems (Fig. 6C,D). Time courses of the PAM occupancy showed that PD81723 
bound typically fast (within ~30 ns) to the ECL2 allosteric site in all the five GaMD simulations (Fig. S6A). 
Accordingly, the E172ECL2-K265ECL3 distance decreased to ~3 Å (Fig. S7B) and the salt bridge stayed mostly closed 
in GaMD simulations of the “A1AR + NECA + PD81723” system (Fig. 6C). In comparison, VCP171 rarely bound 
to the ECL2 allosteric site during two of the five GaMD simulations (Sim3 and Sim4 as shown in Fig. S6B). The 
salt bridge sampled closed, intermediate and open conformations in the “A1AR + NECA + VCP171” system with-
out VCP171 binding to the ECL2, but it was confined to the closed state upon binding of VCP171 to the ECL2 
(Figs 6D and S7C). Therefore, PAM binding to the ECL2 allosteric site biased conformational ensemble of the 
Glu172ECL2-Lys265ECL3 salt bridge towards the closed state, leading to stabilized agonist binding at the orthosteric 
site. This provided important insights into the mechanism of allosteric modulation in the A1AR.
Discussion
In this study, we have determined structural binding modes of prototypical PAMs in the A1AR through extensive 
GaMD enhanced simulations. The GaMD simulations have been performed using the AMBER and NAMD sim-
ulation packages at different acceleration levels. In the GaMD simulations, the A1AR PAMs bound to an allosteric 
site formed by ECL2, a finding that was highly consistent with experimental data26,27. Many of the A1AR residues 
identified within 5 Å of bound PAMs in the GaMD simulations, including ECL2 residues Asn148, Glu153, Ser161, 
Figure 6. PAM binding closed a salt bridge E172ECL2-K265ECL3 in the A1AR extracellular vestibule: (A) A 2D 
PMF profile of the E172ECL2-K265ECL3 distance and NECA RMSD relative to the starting bound conformation 
obtained from AMBER dual-boost GaMD simulation of the “A1AR + NECA” system. The Cδ atom in E172 
and Nζ atom in K265 were used to calculate the distance. (B) Three low-energy states, “Open”, “Intermediate” 
and “Closed”, identified in (A) are shown using the X-ray structure of antagonist DU172-bound A1AR (PDB: 
5UEN), cryo-EM structure of adenosine-Gi-bound A1AR (PDB: 6D9H) and GaMD predicted structure of the 
NECA and PAM PD81723 co-bound A1AR. (C,D) 2D PMF profiles of the E172ECL2-K265ECL3 distance and 
PAM occupancy at the ECL2 allosteric site obtained from AMBER dual-boost GaMD simulations of the (C) 
“A1AR + NECA + PD81723” and (D) “A1AR + NECA + VCP171” systems. PAM binding biased conformation 
ensemble of the E172ECL2-K265ECL3 salt bridge towards the closed state, leading to stabilized agonist binding at 
the orthosteric site.
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Ile167 and Glu172, have previously been suggested to be important for PAM binding in structure-function stud-
ies. These studies demonstrated that alanine substitution of these residues significantly influenced PAM affinity, 
cooperativity and/or efficacy26,27. Therefore, these findings suggest the A1AR PAM allosteric site resides within the 
extracellular vestibule, predominantly involving interactions with ECL2.
Furthermore, the GaMD simulations showed that the PAMs stabilized agonist binding at the A1AR ortho-
steric site. Specifically, compared to simulations performed in the absence of an allosteric ligand, agonist move-
ment within the orthosteric site decreased in the presence of a PAM bound to the ECL2 allosteric site. This was 
correlated with conformational change in the Glu172ECL2-Lys265ECL3 distance in the A1AR extracellular mouth. 
In GaMD simulations of the NECA-bound A1AR system, the Glu172ECL2-Lys265ECL3 salt bridge sampled three 
low-energy conformational states (“Open”, “Intermediate” and “Closed”). Importantly, the open and intermediate 
conformations have been determined in the X-ray structure of antagonist DU172-bound A1AR (PDB: 5UEN)61 
and the cryo-EM structure of adenosine-Gi-bound A1AR (PDB: 6D9H)62, respectively. New high resolution A1AR 
structures co-bound with a PAM and agonist are required to confirm the predicted PAM-mediated stabilization 
of the Glu172ECL2-Lys265ECL3 salt bridge in the closed conformation. Moreover, further GaMD simulations on 
PAM binding to the active A1AR using the recent cryo-EM structure of the adenosine-bound A1AR–Gi complex 
are subject to future study. Nevertheless, the present GaMD simulations have provided important insights into 
the mechanism of allosteric modulation at the A1AR.
In the absence of PAM binding to ECL2, the orthosteric agonist explores a significantly larger conformational 
space and could even dissociate from the A1AR through an opening between ECL2 and ECL3. This pathway 
connecting the orthosteric site and ECL2/ECL3 opening has also been suggested as an energetically preferred 
ligand binding pathway of other class A GPCRs, including the β2AR34, M259 and M3 mAChRs53. An orthosteric 
antagonist ZM241385 has also been observed to dissociate from the A2AAR through a similar pathway in previous 
Anton simulations using TAMD49.
The extracellular allosteric site formed by only the ECL2 appears to be unique in the A1AR. Such an allosteric 
target site has not been identified in other GPCRs so far63. In the M2 receptor, a PAM LY2119620 binds to the 
receptor extracellular vestibule formed by the TM2, TM6 and TM7 in addition to ECL2 as identified in X-ray 
crystallography36 and MD simulations35. Sequence alignment of the four subtypes of ARs showed that while the 
seven TM helix bundle of the A1AR shares high similarity with the A2AAR (71%), A2BAR (70%) and A3AR (77%), 
the similarity is significantly reduced in the ECLs, being 43% for A2AAR, 45% for A2BAR and 35% for A3AR 
when compared with the A1AR. The entire ECL2 has low sequence conservation among the ARs (Fig. S8A). 
Comparison of X-ray structures of the A1AR (PDB: 5UEN)60 with the adenosine-bound A2AAR (PDB: 2YDO)64 
also showed significant differences in the ECL2 conformations. The ECL2 forms a longer helix in the A1AR than 
in the A2AAR and the helix adopts distinct orientations in the two receptors60. Two disulfide bonds, SSB1 and 
SSB2 that anchor ECL2 to ECL1 and Cys3.22 in A2AAR, respectively, are not conserved in the A1AR (Fig. S8B). This 
likely leads to higher flexibility of ECL2 in the A1AR and could play an important role in the binding of selective 
PAMs.
In summary, we have successfully identified a structural binding mode of A1AR PAMs through extensive 
all-atom GaMD simulations that is consistent with previous experimental structure-function analysis. The GaMD 
simulations provide important insights into the allosteric modulation mechanism of the A1AR, predicting that a 
salt bridge between Glu172ECL2-Lys265ECL3 in the A1AR extracellular mouth is closed upon PAM binding to the 
ECL2, leading to stabilized agonist binding within the orthosteric site. The ECL2 appears to serve as the target site 
for A1AR PAMs, as well as an additional metastable binding site for orthosteric agonists. With remarkable diver-
gence of residue sequences and conformations, the ECL2 presents an exciting target site for designing selective 
allosteric drugs of the A1AR. The GaMD simulations, together with mutagenesis data, will greatly facilitate future 
structure-based computer-aided drug design of novel A1AR PAMs.
Methods
Gaussian Accelerated Molecular Dynamics. Gaussian accelerated molecular dynamics (GaMD) is an 
enhanced sampling technique that works by adding a harmonic boost potential to reduce the system energy 
barriers52. GaMD accelerates biomolecular simulations by orders of magnitude. GaMD does not require prede-
fined collective variables. Compared with the enhanced sampling methods that rely on careful selection of the 
collective variables, GaMD is of particular advantage for studying “free” protein-ligand binding processes37,52. 
Moreover, because the boost potential follows a Gaussian distribution, biomolecular free energy profiles can be 
properly recovered through cumulant expansion to the second order52. GaMD thus solves the energetic reweight-
ing problem as encountered in the previous aMD method50,65 for free energy calculations. GaMD has been imple-
mented in the widely used AMBER52,66 and NAMD53 packages. It has allowed us to characterize protein folding, 
protein-ligand binding, protein-protein binding and protein-nucleic acid interactions52,53,59,67,68. Details of the 
method have been described in previous studies52,53. A brief summary is provided here.
Consider a system with N atoms at positions r = {r 1 …,r N}. When the system potential V( r) is lower than 
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where k is the harmonic force constant. The two adjustable parameters E and k are automatically determined 
based on three enhanced sampling principles52. The reference energy needs to be set in the following range:
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where Vmax and Vmin are the system minimum and maximum potential energies. To ensure that Eqn. (2) is valid, 












, then 0 < k0 ≤ 1. The standard deviation of ΔV needs 
to be small enough (i.e., narrow distribution) to ensure proper energetic reweighting69: σ σ σ= − ≤∆ ( )k E VV avg V 0 
where Vavg and σV are the average and standard deviation of the system potential energies, σΔV is the standard 
deviation of ΔV with σ0 as a user-specified upper limit (e.g., 10 kBT) for proper reweighting. When E is set to the 
lower bound E = Vmax, k0 can be calculated as:
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Alternatively, when the threshold energy E is set to its upper bound = +E Vmin k





















if ″k 0 is found to be between 0 and 1. Otherwise, k0 is calculated using Eqn. (3).
Similar to aMD, GaMD provides options to add only the total potential boost ΔVP, only dihedral potential 
boost ΔVD, or the dual potential boost (both ΔVP and ΔVD). The dual-boost simulation generally provides 
higher acceleration than the other two types of simulations for enhanced sampling51. The simulation parameters 
comprise of the threshold energy values and the effective harmonic force constants, k0P and k0D for the total and 
dihedral potential boost, respectively.
For energetic reweighting of GaMD simulations to calculate potential of mean force (PMF), the probability 
distribution along a reaction coordinate is written as p*(A). Given the boost potential ΔV r( ) of each frame, p*(A) 
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where the first two cumulants are given by:
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The boost potential obtained from GaMD simulations usually follows near-Gaussian distribution68. Cumulant 
expansion to the second order thus provides a good approximation for computing the reweighting factor52,69. The 
reweighted free energy F(A) = −kBT ln p(A) is calculated as:
∑ β= − +
=
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where F*(A) = −kBT ln p*(A) is the modified free energy obtained from GaMD simulation and Fc is a constant.
System Setup. The first X-ray crystal structure of the A1AR (PDB: 5UEN)60 was used to set up the simu-
lation system. After removal of antagonist, the NECA agonist was placed in the orthosteric pocket with atomic 
coordinates extracted from the A2AAR X-ray structure (PDB: 2YDV) after aligning the two receptor transmem-
brane domains. Four molecules of each PAM (PD81723 and VCP171) were initially placed >20 Å away from the 
receptor.
Two systems “A1AR + NECA + PD81723” and “A1AR + NECA + VCP171” were prepared for the simulations. 
In addition, the system NECA-bound A1AR in the absence of PAMs was also added for comparison (Table 1) The 
protein that was fused into the receptor to replace intracellular loop 3 (ICL3) for crystallizing the receptor struc-
ture was omitted. All chain termini were capped with neutral groups (acetyl and methylamide). The disulphide 
bonds that were resolved in the crystal structure were maintained in the simulations. Using the psfgen plugin in 
VMD70, protein residues were set to the standard CHARMM protonation states at neutral pH. Then the receptor 
was inserted into a palmitoyl-oleoyl-phosphatidyl-choline (POPC) bilayer with all overlapping lipid molecules 
removed using the Membrane plugin in VMD70. The system charges were then neutralized at 0.15 M NaCl using 
the Solvate plugin in VMD70. The simulation systems of the A1AR initially measured about 97 × 85 × 106 Å3 with 
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152 lipid molecules, ~15,600 water molecules and a total of ~72,300 atoms. Periodic boundary conditions were 
applied on the simulation systems.
Simulation Protocols. The CHARMM36 parameter set71 was used for the protein and POPC lipids. For 
agonist NECA and PAMs PD81723 and VCP171, the force field parameters were obtained from the CHARMM 
ParamChem web server27,72. Initial energy minimization and thermalization of the A1AR system follow the same 
protocol as used in the previous GPCR simulations58. In the present GaMD simulation, the threshold energy E for 
adding boost potential is set to the lower bound52,53. The simulations included 2 ns cMD, 50 ns equilibration after 
adding the boost potential and then multiple independent production runs lasting 200–500 ns with randomized 
atomic velocities. The GaMD simulations are summarized in Table 1.
For the “A1AR + NECA” and “A1AR + NECA + PD81723” systems, GaMD simulations were performed 
using AMBER at the dual-boost level52, and NAMD at the dual-boost and dihedral acceleration levels53. For the 
“A1AR + NECA + VCP171” system, dual-boost GaMD simulations using AMBER were performed. The GaMD 
simulations were carried out using AMBER 1652,73 and/or NAMD2.1353,74. GaMD production frames were saved 
every 0.1 ps for analysis.
Simulation Analysis. The VMD70 and CPPTRAJ75 tools were used for trajectory analysis. The Density Based 
Spatial Clustering of Applications with Noise (DBSCAN) algorithm76 was applied to cluster the diffusing ligand 
molecules for identifying their highly populated binding conformations. The frames were sieved at a stride of 
200 for clustering. The remaining frames were assigned to the closest cluster afterwards. The distance cutoff for 
DBSCAN clustering was set to 4 Å for the PAMs and 1.5 Å for the NECA agonist. Finally, the PyReweighting 
toolkit69 was applied to compute free energy values of the ligand structural clusters.
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